[go: up one dir, main page]

ES8705036A1 - Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana - Google Patents

Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Info

Publication number
ES8705036A1
ES8705036A1 ES552539A ES552539A ES8705036A1 ES 8705036 A1 ES8705036 A1 ES 8705036A1 ES 552539 A ES552539 A ES 552539A ES 552539 A ES552539 A ES 552539A ES 8705036 A1 ES8705036 A1 ES 8705036A1
Authority
ES
Spain
Prior art keywords
making
membrane bound
bound proteins
vaccines based
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES552539A
Other languages
English (en)
Other versions
ES552539A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8705036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES8705036A1 publication Critical patent/ES8705036A1/es
Publication of ES552539A0 publication Critical patent/ES552539A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE UNA VACUNA OBTENIDA A PARTIR DE PROTEINAS FIJADAS A MEMBRANAS Y CON DERIVADOS DE LAS MISMAS. COMPRENDE LAS SIGUIENTES OPERACIONES: PRIMERA, SE PREPARA UN ACIDO DESOXIRRIBONUCLEICO QUE COIDIFICA UN POLIPEPTIDO FIJADO A UNA MEMBRANA, CARECIENDO DICHO POLIPEPTIDO DE CODIFICACION PARA DOMINIO DE FIJACION A MEMBRANAS; SEGUNDA, SE INCORPORA EL ACIDO DESOXIRRIBONUCLEICO EN UN VECTOR DE EXPRESION; TERCERA, SE TRANSFECTA UNA CELULA HOSPEDANTE CON DICHO VECTOR; Y POR ULTIMO, SE RECOGE EL POLIPEPTIDO COMO UN PRODUCTO DE SECRECION. DE APLICACION EN MEDICINA, EN TRATAMIENTOS DE INFECCIONES HUMANAS.
ES552539A 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana Expired ES8705036A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52791783A 1983-08-30 1983-08-30
US54755183A 1983-10-31 1983-10-31
US58817084A 1984-03-09 1984-03-09

Publications (2)

Publication Number Publication Date
ES8705036A1 true ES8705036A1 (es) 1987-05-01
ES552539A0 ES552539A0 (es) 1987-05-01

Family

ID=27414978

Family Applications (2)

Application Number Title Priority Date Filing Date
ES535554A Expired ES8605039A1 (es) 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
ES552539A Expired ES8705036A1 (es) 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES535554A Expired ES8605039A1 (es) 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.

Country Status (13)

Country Link
US (1) US5851533A (es)
EP (1) EP0139417B2 (es)
JP (2) JP2599350B2 (es)
AU (1) AU579323B2 (es)
CA (1) CA1341181C (es)
DE (1) DE3479085D1 (es)
DK (2) DK172694B1 (es)
ES (2) ES8605039A1 (es)
GR (1) GR80220B (es)
HK (1) HK98792A (es)
IE (1) IE58030B1 (es)
IL (1) IL72785A (es)
NZ (1) NZ209308A (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
GR862472B (en) * 1986-09-30 1986-10-09 Elliniko Institouto Paster Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
WO1991002061A1 (en) * 1989-07-31 1991-02-21 Basil Rapaport Recombinant human thyroid peroxidase
EP0541692B1 (en) * 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
EP0668918A1 (en) * 1991-08-28 1995-08-30 Institute Diagnostics Nichols Disease associated human autoantibodies specific for human thyroid peroxidase
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
WO2002016420A2 (en) * 2000-08-01 2002-02-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds derived from the hsv gd protein and methods
EP1412381B1 (en) 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2006058000A1 (en) 2004-11-24 2006-06-01 Shell Internationale Research Maatschappij B.V. Separator for multi-phase slug flow and method of designing same
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
CN101616688B (zh) * 2006-12-28 2013-12-11 宾夕法尼亚大学理事会 单纯疱疹病毒联合亚单位疫苗及其使用方法
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2010249330B2 (en) * 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
SI2506832T1 (sl) 2009-12-03 2014-06-30 Novartis Ag Hidrofilna filtracija med izdelavo adjuvantov za cepiva
CN104997730B (zh) 2009-12-03 2018-04-06 诺华股份有限公司 就微流化排列交互作用和背压室
DK2356983T3 (da) 2009-12-03 2013-03-11 Novartis Ag Cirkulation af bestanddele under homogenisering af emulsioner
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
KR101875894B1 (ko) 2010-05-12 2018-08-02 노파르티스 아게 스쿠알렌을 제조하기 위한 개선된 방법
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
US20230218526A1 (en) 2020-06-30 2023-07-13 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
AU559550B2 (en) * 1981-03-09 1987-03-12 Cetus Corporation Vaccines
EP0068693A3 (en) 1981-06-16 1983-07-20 Genentech, Inc. Production of foot and mouth disease vaccine from microbially expressed antigens
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
DK305784A (da) * 1983-06-23 1984-12-24 Stanley Person Ikke-glycosyleret aminosyrekaede af glycoprotein b fra herpes virus type 1 og 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
WO1985004587A1 (en) * 1984-04-06 1985-10-24 Chiron Corporation RECOMBINANT HERPES SIMPLEX gB-gD VACCINE
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
EP0170169B1 (en) * 1984-07-20 1991-03-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant dna containing a herpes simplex virus gene or a fragment thereof, yeast transformed with said recombinant dna, and method for the production of herpes simplex virus proteins

Also Published As

Publication number Publication date
IL72785A (en) 1990-07-26
IL72785A0 (en) 1984-11-30
NZ209308A (en) 1991-08-27
ES535554A0 (es) 1986-03-16
IE58030B1 (en) 1993-06-16
US5851533A (en) 1998-12-22
EP0139417A1 (en) 1985-05-02
AU3242384A (en) 1985-03-07
JPH08253428A (ja) 1996-10-01
GR80220B (en) 1984-11-15
DK412284D0 (da) 1984-08-29
EP0139417B2 (en) 1999-03-17
JPS60155128A (ja) 1985-08-15
ES8605039A1 (es) 1986-03-16
DE3479085D1 (en) 1989-08-31
DK412284A (da) 1985-04-11
AU579323B2 (en) 1988-11-24
HK98792A (en) 1992-12-18
DK9197A (da) 1997-01-24
EP0139417B1 (en) 1989-07-26
DK172694B1 (da) 1999-05-31
ES552539A0 (es) 1987-05-01
CA1341181C (en) 2001-02-20
JP2599350B2 (ja) 1997-04-09
IE842210L (en) 1985-02-28

Similar Documents

Publication Publication Date Title
ES8605039A1 (es) Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
SG48422A1 (en) Yeast expression systems with vectors having gapdh promoters and synthesis of hbsag
EG17879A (en) Non-toxinogenic vibrio cholerae nutants
EP0101506A4 (en) MATERIAL AND METHOD FOR HERPES SIMPLEX VIRUS Vaccination.
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
WO1989007136A3 (en) Modified hepatocytes and uses therefor
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
ES8604693A1 (es) Un metodo para detectar un anticuerpo o un antigeno contenido en una muestra de fluido de origen biologico.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
NO910479L (no) Syntetiske polypeptider og antistoffer relatert til epstein-barr-virus-kjerneantigen.
ES8800342A1 (es) Procedimiento para preparar un vector de levadura de copias multiples,estables y recombinante
AU5507786A (en) Process for the preparation of an antigen specific to herpes simplex virus type 2, agents suitable for this purpose, and the use of this antigen
ZA831097B (en) Materials and methods for herpes simplex virus vaccination
GT198304126A (es) Produccion de proteinas del virus de herpes simplex
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
NZ334582A (en) Polyprotein construct of a papillomavirus

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070307